Tirzepatide vs CJC-1295
A comprehensive, data-driven comparison of Tirzepatide (Mounjaro) and CJC-1295 (Modified GRF 1-29). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Tirzepatide Mounjaro, Zepbound | CJC-1295 Modified GRF 1-29, DAC:GRF |
|---|---|---|
| FDA Status | FDA Approved | Category 2 (pending reclassification) |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Type 2 diabetes, chronic weight management, and obstructive sleep apnea | Growth hormone optimization and anti-aging |
| Weight Loss % | 22.5% | N/A |
| Monthly Cost | $1,100 - $1,100/mo | $35 - $70/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 15mg weekly (max dose) | 1-2mg twice weekly (with DAC) |
| Frequency | Weekly | Twice weekly |
| Mechanism | Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Emerging |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1Tirzepatide is FDA-approved, while CJC-1295 is currently category 2 (pending reclassification).
- 2Tirzepatide has clinical weight loss data (22.5%), while CJC-1295 is not primarily indicated for weight loss.
- 3CJC-1295 is generally more affordable ($35 - $70/mo) compared to Tirzepatide ($1,100 - $1,100/mo).
- 4Tirzepatide is dosed weekly, while CJC-1295 is twice weekly.
- 5Tirzepatide has high-quality evidence, while CJC-1295 has emerging-quality evidence.
- 6They belong to different categories: Tirzepatide (Weight Loss) vs CJC-1295 (Growth Hormone).
Which Is Better For...
Tirzepatide
Those seeking an FDA-approved treatment with established safety data
CJC-1295
More budget-friendly option with lower monthly costs
Tirzepatide
More convenient dosing schedule (weekly)
CJC-1295
Fewer commonly reported side effects
Tirzepatide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Tirzepatide | $1,100 - $1,100/mo | FDA Approved | Eli Lilly |
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. They differ in FDA approval status, efficacy data, and cost.
Tirzepatide has demonstrated 22.5% average weight loss in clinical trials. CJC-1295 is not primarily used for weight loss.
Tirzepatide typically costs $1,100 - $1,100/mo, while CJC-1295 costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Tirzepatide is FDA-approved. CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Tirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. In December 2024, Zepbound became the first and only medication approved fo...
View Full Tirzepatide GuideCJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tirzepatide and CJC-1295 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.